Skip to Content
Merck
  • eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.

eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.

The Journal of investigative dermatology (2015-01-07)
Shahram Khosravi, Kevin J Tam, Gholamreza S Ardekani, Magdalena Martinka, Kevin J McElwee, Christopher J Ong
ABSTRACT

Human cutaneous melanoma is a devastating skin cancer because of its invasive nature and high metastatic potential. We used tissue microarray to study the role of human eukaryotic translation initiation factor 4E (eIF4E) in melanoma progression in 448 melanocytic lesions and found that high eIF4E expression was significantly increased in primary melanomas compared with dysplastic nevi (P<0.001), and further increased in metastatic melanomas (P<0.001). High eIF4E expression was associated with melanoma thickness (P=0.046), and poor overall and disease-specific 5-year survival of all, and primary melanoma patients, especially those with tumors ≥1 mm thick. Multivariate Cox regression analysis revealed that eIF4E is an independent prognostic marker. eIF4E knockdown (KD) in melanoma cells resulted in a significant increase in apoptosis (sub-G1 populations) and decrease in cell proliferation, and also resulted in downregulation of mesenchymal markers and upregulation of E-cadherin. In addition, eIF4E KD led to a decrease in melanoma cell invasion, matrix metalloproteinase-2 expression and activity, c-myc and BCL2 expression, and an increase in cleaved PARP and cleaved caspase-3 expression and chemosensitivity. Taken together, our data suggest that the eIF4E may promote melanoma cell invasion and metastasis, and may also serve as a promising prognostic marker and a potential therapeutic target for melanoma.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Trimesic acid, 95%
Sigma-Aldrich
Trimethylaluminum solution, 2.0 M in toluene